Islam Nadia, Budvytyte Laura, Khera Nandita, Hilal Talal
Mayo Clinic Alix School of Medicine, Scottsdale, AZ, 85254, USA.
Division of Hematology/Oncology, Mayo Clinic, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA.
Curr Hematol Malig Rep. 2024 Dec 4;20(1):1. doi: 10.1007/s11899-024-00747-6.
Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments, and impact the generalizability of trials, compromising health outcomes across different populations. This review aims to examine the persistent disparities noted in clinical trial enrollment, with particular focus on lymphoid malignancies, CAR-T cell and bispecific antibody therapies.
Targeted interventions can enhance recruitment of underrepresented groups in clinical trials and address the complex barriers hindering participation, which are essential for achieving healthcare access equity and treatment outcomes. Improvement must be multifaceted, addressing socioeconomic, geographic, and biologic factors contributing to underrepresentation. This includes more lenient eligibility criteria, improving outreach and education, as well as using technology to diversify trial participation.
近期研究表明，未解决的差异阻碍了临床试验的入组、治疗的公平分配，并影响试验的可推广性，损害了不同人群的健康结果。本综述旨在研究临床试验入组中存在的持续差异，特别关注淋巴系统恶性肿瘤、嵌合抗原受体T细胞（CAR-T）和双特异性抗体疗法。
有针对性的干预措施可以提高临床试验中代表性不足群体的招募率，并解决阻碍参与的复杂障碍，这对于实现医疗保健可及性公平和治疗结果至关重要。改进必须是多方面的，要解决导致代表性不足的社会经济、地理和生物学因素。这包括更宽松的入选标准、改善宣传和教育，以及利用技术使试验参与多样化。
